Table 2.
Changes in the clinical characteristics of the patients in the TwHF group and valsartan group during the follow-up period
| |
Baseline |
Month 1 |
Month 3 |
Month 6 |
P value calculated by repeated-measures ANOVA |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TwHF (n = 34) | Valsartan (n = 31) | TwHF (n = 33) | Valsartan (n = 29) | TwHF (n = 33) | Valsartan (n = 25) | TwHF (n = 29) | Valsartan (n = 26) | Time | Group | Time × Group | |
| Systolic blood pressure (mmHg) |
140.6 ± 15.8 |
138.4 ± 16.6 |
135.1 ± 14.3 |
139.4 ± 16.2 |
137.9 ± 14.6 |
138.6 ± 19.7 |
137.4 ± 14.4 |
141.9 ± 18.4 |
0.455 |
0.943 |
0.408 |
| Diastolic blood pressure (mmHg) |
81.6 ± 11.9 |
85.0 ± 10.8 |
79.8 ± 10.3 |
78.7 ± 10.3 |
79.1 ± 10.0 |
77.7 ± 8.8 |
79.5 ± 8.5 |
76.5 ± 10.5 † |
0.03 |
0.574 |
0.253 |
| Urine protein (g/24 h) |
4.99 ± 2.25 |
4.15 ± 1.29 |
3.23 ± 2.57**# |
3.92 ± 1.56 |
2.83 ± 1.57**# |
3.59 ± 1.71 |
2.99 ± 1.81**# |
4.40 ± 2.37 |
<0.001 |
0.115 |
0.001 |
| Serum albumin (g/L) |
33.0 ± 5.66 |
33.0 ± 4.69 |
33.2 ± 5.35 # |
37.7 ± 4.25‡ |
33.9 ± 5.3 |
37.4 ± 4.64‡ |
34.8 ± 5.49 |
36.3 ± 5.47‡ |
<0.001 |
0.368 |
<0.001 |
| eGFR (ml/min/1.73 m2) | 43.07 ± 21.65 | 47.72 ± 20.34 | 38.82 ± 19.93 | 43.59 ± 17.41 | 40.23 ± 22.24 | 39.33 ± 16.79‡ | 38.71 ± 23.66* | 36.22 ± 14.96‡ | <0.001 | 0.682 | 0.009 |
* p < 0.05 vs. TwHF baseline; **p < 0.01 vs. TwHF baseline.
† p < 0.05 vs. Valsartan baseline; ‡ p < 0.01 vs. Valsartan baseline.
# p < 0.05 vs. Valsartan group at the same follow-up.